Biomarin Pharmaceutical
Open
$54.69
Prev. Close
$54.69
High
$54.71
Low
$54.69
Market Snapshot
$10.41B
29.8
2.25
$2.85B
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,221 full-time employees. The firm has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
emptyResult
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,221 full-time employees. The firm has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
Recently from Cashu
CNBC Cures: Boosting Awareness and Support for Rare Disease Patients
Creating Awareness for Rare Diseases: CNBC Cures Makes an Impact In an inspiring move to raise awareness for the 30 million Americans affected by rare diseases, CNBC has launched an initiative named "…
Insider Sale Raises Concerns Over BioMarin's Strategic Confidence Amid Development Efforts
Insider Sale Raises Questions Amid BioMarin’s Ongoing Development BioMarin Pharmaceutical, a leader in biotechnology focused on treatments for rare diseases, finds itself in the spotlight following th…
BioMarin's VOXZOGO® Demonstrates Early Treatment Benefits for Children with Achondroplasia
BioMarin’s VOXZOGO® Shows Promising Results in Early Treatment for Achondroplasia BioMarin Pharmaceutical Inc. announces encouraging findings from its studies on VOXZOGO® (vosoritide), which reaffirm…
Biomarin Pharmaceutical's Commitment to Innovating Rare Disease Treatments and Market Growth
Advancements in Rare Disease Treatments: A Focus on Biomarin Pharmaceutical In the rapidly evolving landscape of biotechnology, Biomarin Pharmaceutical stands out for its commitment to addressing rare…